Idelvion

Albutrepenonacog Alfa, the active ingredient in Idelvion, is a recombinant factor IX presented as a sterile solution for injection for intravenous administration. It is used to replace deficient factor IX activity in patients with hemophilia B, helping to restore normal coagulation and prevent or control bleeding episodes.

GNH USA supplies Idelvion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialized therapy for hemophilia B patients through regulated supply chains and quality‑assured logistics.

Idelvion is a recombinant factor IX product used in the management of hemophilia B, a factor IX deficiency disorder. - Hemophilia B prophylaxis: reduces the frequency of spontaneous bleeding by maintaining baseline factor IX activity. - Treatment of bleeding episodes in hemophilia B: provides rapid factor IX replacement to control acute bleeds. - Perioperative management in hemophilia B: maintains hemostasis during surgical procedures.

Common Side Effects: - Infusion‑related reactions: redness, warmth, or itching at the injection site. - Headache: mild to moderate intensity. - Nausea or vomiting: occasional gastrointestinal discomfort. - Fever: low‑grade temperature elevation. - Arthralgia: joint pain without swelling. - Mild rash: transient skin erythema.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Development of factor IX inhibitors: neutralizing antibodies that reduce efficacy. - Thrombotic events: unexpected clot formation. - Severe hypersensitivity: swelling of face, lips, or throat. - Hemolysis: breakdown of red blood cells. - Elevated liver enzymes: indication of hepatic stress.

Idelvion should be used with individualized dosing determined by the prescribing clinician. - Bleeding risk monitoring: observe patients for signs of uncontrolled bleeding. - Inhibitor development: regularly assess for emergence of factor IX inhibitors. - Pregnancy and lactation: consider use only if potential benefits outweigh risks. - Renal or hepatic impairment: adjust monitoring as clinically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idelvion may interact with other medicines that affect coagulation. Major Interactions (Avoid): - Concurrent use of procoagulant agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk. - Concomitant anticoagulants (e.g., warfarin, direct oral anticoagulants) may reduce the efficacy of factor IX replacement. - Use with immune‑modulating therapies may affect inhibitor development. Moderate Interactions (Monitor Closely): - Vaccines, especially live attenuated, may require timing adjustments. - Antibiotics that alter gut flora may influence immune response to the protein. - Other plasma‑derived products may increase the risk of hypersensitivity reactions.